HIV and Hepatitis.com Coverage of the
13th Annual Conference on Retroviruses and Opportunistic Infections
February 5 - 8, 2006, Denver, CO

Experimental Antiretrovirals

Experimental Entry Inhibitor PRO 140 Wins "Fast Track" Designation from FDA

Combination of Boosted Tipranavir and Experimental PI TMC 125 Is Not Recommended

Encouraging Data at 13th CROI on Novel New HIV Protease Inhibitor TMC 114 and Unique Non Nucleoside TMC 125

Schering Revives Study of Experimental CCR5 Entry Inhibitor Vicriviroc in Treatment-naïve HIV Patients

Phase 1/ 2 Data Presented on Experimental Integrase Inhibitor GS 9137 from Gilead Sciences

Merck Announces Interim Results from Phase II Study of MK-0518, an Investigational Oral HIV Integrase Inhibitor